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PERSPECTIVE
Clinical application of brain imaging for the diagnosis of mood
disorders: the current state of play
JB Savitz
1,2, SL Rauch
3,4 and WC Drevets
1,5
In response to queries about whether brain imaging technology has reached the point where it is useful for making a clinical
diagnosis and for helping to guide treatment selection, the American Psychiatric Association (APA) has recently written a position
paper on the Clinical Application of Brain Imaging in Psychiatry. The following perspective piece is based on our contribution to this
APA position paper, which speciﬁcally emphasized the application of neuroimaging in mood disorders. We present an introductory
overview of the challenges faced by researchers in developing valid and reliable biomarkers for psychiatric disorders, followed by a
synopsis of the extant neuroimaging ﬁndings in mood disorders, and an evidence-based review of the current research on brain
imaging biomarkers in adult mood disorders. Although there are a number of promising results, by the standards proposed below,
we argue that there are currently no brain imaging biomarkers that are clinically useful for establishing diagnosis or predicting
treatment outcome in mood disorders.
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OVERVIEW OF APPLICATIONS OF NEUROIMAGING IN
PSYCHIATRIC DISORDERS
The application of neuroimaging technology in psychiatric
research has revolutionized clinical neuroscience perspectives on
the pathophysiology of the major psychiatric disorders. Research
using a variety of types of neuroimaging techniques has shown
that these conditions are associated with abnormalities of brain
function, structure and receptor pharmacology. These data also
corroborate the conclusions reached from genetic, endocrine, and
clinical pharmacology research involving these disorders to
suggest that under the current nosology the major psychiatric
disorders likely reﬂect heterogenous groups of disorders with
respect to pathophysiology and etiology.
Despite the invaluable leads that the neuroimaging studies
have provided regarding the neurobiological bases for psychiatric
disorders, they have yet to impact signiﬁcantly the diagnosis or
treatment of individual patients. In clinical medicine, considerable
interest has existed in developing objective, biologically based
tests for psychiatric illnesses. From the clinical perspective, such
advances could yield important beneﬁts such as predicting
treatment response, differentiating between related diagnostic
categories, and potentially treating at-risk patients prophylactically
to prevent neurotoxicity and clinical deterioration.
Nevertheless, the effect size of neuroimaging and other
biological abnormalities identiﬁed to date in psychiatric disorders
has been relatively small, such that imaging measures do not
provide sufﬁcient speciﬁcity and sensitivity to accurately classify
individual cases with respect to the presence of a psychiatric
illness. This review focuses speciﬁcally on the potential clinical
utility of biomarkers assessed using modern neuroimaging
technologies, and the approach required to validate imaging
biomarkers for use as clinical diagnostics.
The quest for biomarkers in psychiatry
Both the clinical practice of psychiatry and the development of
novel therapeutics have been hindered by the lack of
biomarkers that can serve as accessible, objective indices of the
complex biological phenomena that underpin psychiatric
illness. The inaccessibility of brain tissue, the lack of knowledge
about pathophysiology and the uncertain link between
abnormal measurements on any biological test and pathogenesis
all have impeded the development of biomarkers for psychiatric
disorders. As a result, progress toward improving diagnostic
capabilities and deﬁning or predicting treatment outcome in
psychiatry has lagged behind other areas of medicine. Thus, it
frequently remains difﬁcult to establish whether individual
patients suffer from a particular disease, how individual patients
can best be treated, and whether experimental treatments are
effective in general.
The need for clinical biomarkers has become acute, as their
absence particularly has hindered research aimed at developing
novel therapeutics. Due at least partly to the lack of
well-established pathophysiological targets for new drugs, rela-
tively large numbers of experimental compounds are failing in
increasingly expensive late-stage clinical trials. As a result, drug
development pipelines are becoming dry, and several companies
have discontinued their research and development of pharma-
ceuticals for psychiatric conditions. The ramiﬁcations of these
limitations for clinical practice also are signiﬁcant, as psychiatric
nosology and diagnosis largely have remained at a standstill.
Since the development of Diagnostic and Statistical Manual of the
American Psychiatric Association (DSM)-III, the clinical approach to
treatment decisions for individual patients remains empirical (‘trial
and error’), and many patients are inadequately helped by extant
treatments.
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For over two decades, imaging has maintained a well-established
but narrow place in the diagnostic evaluation of patients with
psychiatric disease, largely because of the usefulness of neuromor-
phological magnetic resonance imaging (MRI) in detecting and
characterizing structural brain abnormalities such as lesions and
atrophy. Thus, the role of imaging in patients with psychopathology
historically has been limited to one of exclusion of potentially
etiological medical conditions: namely to rule out neoplasm,
hematoma, hydrocephalus or other potentially surgically treatable
causes of psychiatric symptoms, or to detect the presence of
cerebrovascular disease or gross atrophy. Although clinically
important, these conditions appear to have a role in the
pathogenesis of psychiatric symptoms in only a small proportion
of cases presenting for the evaluation of mood, anxiety or psychotic
disorders.
Increasingly, a major quest of researchers has been to identify
neuroimaging results that offer diagnostic capabilities for
particular psychiatric diseases as well as for their relevant
differential diagnoses. Currently, neuroimaging is not recom-
mended within either the US or the European practice guidelines
for positively deﬁning diagnosis of any primary psychiatric
disorder. Nevertheless, advances in research applications of
neuroimaging technology have provided leads that may fore-
shadow future clinical applications of imaging biomarkers for
establishing diagnosis and predicting illness course or treatment
outcome. The ensuing review discusses issues that have been
addressed within other areas of clinical medicine to establish the
validity and reliability of imaging diagnostics, with the aim of
providing principles to guide the evaluation of neuroimaging
applications in clinical psychiatry.
BIOMARKER DEFINITION, VALIDATION AND QUALIFICATION
The National Institutes of Health has deﬁned a biomarker (that is,
biological marker) as: ‘A characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes,
pathogenic processes or pharmacologic responses to a therapeu-
tic intervention.’
1 A biomarker thus can deﬁne a physiological,
pathological or anatomical characteristic or measurement that
putatively relates to some aspect of either normal or abnormal
biological function. Biomarkers thus may assess many different
types of biological characteristics or parameters, including
receptor expression patterns, radiographic or other imaging-
based measures, or electrophysiologic parameters.
Furthermore, the term ‘biomarker’ connotes different meanings
in different contexts, based upon the intended application of the
information a biomarker provides. Within clinical medicine,
biomarkers include measures that suggest the etiology of,
susceptibility to, activity levels of, or progress of a disease. In
addition, alterations in patient-associated biomarkers related to an
intervention may be used to predict the likelihood of experiencing
a robust clinical outcome or an adverse reaction to a treatment.
Finally, in drug development a biomarker can be any measure of
drug action that is proximal to its clinical effect, including
biomarkers that correlate with drug response or quantify the
extent to which a drug occupies speciﬁc receptors in a target tissue.
Notably, the US Food and Drug Administration (FDA) and the
European Medicines Agency recently have jointly developed
guidance that addresses multiple types of biomarkers that can be
applied to drug development, including prognostic, predictive,
pharmacodynamic and surrogate biomarkers. A prognostic bio-
marker is a baseline patient or disease characteristic that
categorizes patients by degree of risk for disease occurrence or
progression. A predictive biomarker is a baseline characteristic that
categorizes patients by their likelihood for response to a particular
treatment. A pharmacodynamic biomarker is a dynamic assess-
ment that shows that a biological response has occurred in a
patient after having received a therapeutic intervention. A
surrogate end point is deﬁned as a biomarker intended to
substitute for a clinical efﬁcacy end point. Conceivably, each of
these biomarker types holds the potential to be clinically useful in
psychiatric research or practice. Nevertheless, in its guidance the
FDA identiﬁed the most valuable role for biomarkers as their use
in clinical diagnostics.
In considering the development of neuroimaging biomarkers as
clinical diagnostics, the FDA guidance on biomarkers for drug
development merits comment. Generally, the requirements of
biomarkers for quantiﬁcation of drug effects in research and
development, which depend upon population means with
variance estimates, converge with the requirements of diagnostics
in clinical practice, which are assessed on a per-patient basis. The
common element in both is longitudinal quantiﬁcation; both
analyses require baseline and follow-up effects of treatments. For
example, clinical evidence from the National Oncologic positron
emission tomography (PET) Registry motivated the expanded
coverage by Medicare for ﬂuorodeoxyglucose-PET/CT (computed
tomography) in the detection and staging of cancer and in the
monitoring of cancer treatment response. Thus as diagnostics,
biomarkers are of interest to health-care providers and consumers
for parallel applications, since earlier detection of disease
facilitates earlier intervention, which, when followed by effective,
individualized treatment, can improve patient outcomes.
With respect to establishing the utility of a biomarker, it is useful
to distinguish between the terms ‘validation’ and ‘qualiﬁcation’.
Validation generally refers to the determination of the perfor-
mance characteristics of a measurement—for example, the
measurement’s reliability, sensitivity and speciﬁcity—in measuring
a particular biological construct. The validation process is
particularly relevant for securing regulatory approval to market
techniques for commercial use as clinical diagnostics, as described
in the subsequent section.
The term qualiﬁcation refers to the establishment of the
credibility of a biomarker in its application to questions speciﬁcally
relevant to drug development. In drug development, the ultimate
use of a biomarker is as a surrogate end point, which requires
that the biomarker has been qualiﬁed to substitute for a clinical
standard of truth (that is, the biomarker reasonably predicts the
clinical outcome and therefore can serve as a surrogate). After a
biomarker is ‘qualiﬁed’ by the FDA (or other regulatory agency),
industry can use the markers in a similar context in multiple
drug trials, drug classes or clinical disorders, without having
to repeatedly seek the agency’s approval (‘Qualiﬁcation Process
for Drug Development Tools’; http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM230597.pdf).
The FDA qualiﬁcation process for biomarkers also encompasses
guidance on drug-development tools, including radiographic
or other imaging-based measurements. Qualiﬁcation of a drug-
development tool is based on a conclusion that within the stated
context of use, the results of assessment with the tool can be
relied upon to have a speciﬁc interpretation and application
under regulatory review. The FDA guidance indicates ‘While a
biomarker cannot become qualiﬁed without a reliable means to
measure the biomarker, FDA clearance of a measurement device
does not imply that the biomarker has been demonstrated
to have a qualiﬁed use in drug development and evaluation.’
Instead the qualiﬁcation process is limited to speciﬁc patient
populations and a speciﬁc therapeutic intervention. In addition
to the biomarker assay validation data, clinical data are required
to support the biomarker qualiﬁcation. A corollary of this
regulatory principle is that the FDA qualiﬁcation of a drug-
development tool for one application does not extend to its use in
other applications.
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The validity of a diagnostic biomarker for any medical disorder
generally is established via evaluation of its sensitivity, speciﬁcity,
prior probability, positive predictive value and negative predictive
value.
2 Sensitivity refers to the capacity of a biomarker to identify a
substantial percentage of patients with the disease-of-interest
(expressed as: true positive cases divided by (true positive cases
plus false negative cases) 100). Thus, a sensitivity of 100%
corresponds to a marker that identiﬁes 100% of patients with the
target condition. Speciﬁcity refers to the capacity of a test to
distinguish the target condition from normative conditions
(for example, aging) and other pathological conditions
(expressed as: true negatives divided by (true negative cases
plus false positive cases) 100). A test with 100% speciﬁcity would
be capable of differentiating the target condition from other
conditions in every case. Prior probability is deﬁned as the
frequency of occurrence of a disease in a particular population
(true positives plus false negatives divided by the total
population). A perfect biomarker would detect only true
positives and no false negatives and thus would reﬂect
accurately the prevalence of the disease in the population.
Positive predictive value is the percentage of people who have a
positive test who can be shown by a deﬁnitive examination (for
example, subsequent autopsy or biopsy) to have the disease (true
positives divided by (true positives plus false positives)). A positive
predictive value of 100% indicates that all patients with a positive
test actually have the disease. For a biomarker to be considered
useful clinically, it generally is expected to show a positive
predictive value of B 80% or more.
3 Negative predictive value
represents the percentage of people with a negative test that
subsequently proves not to have the disease on deﬁnitive
examination (true negatives divided by (true negatives plus false
negatives)). A negative predictive value of 100% indicates that the
test completely rules out the possibility that the individual has the
disease, at least at the time the individual is tested. A reliable
marker with a high negative predictive value is extremely useful in
clinical medicine, although a test with low negative predictive
value can in some cases still be useful if it also has high positive
predictive value.
In the development of medical tests, the threshold for
distinguishing abnormal from normal alters the sensitivity and
speciﬁcity in opposite ways. Thus, if the threshold is set further from
the distribution of normative values then the test becomes less
sensitive for detecting true positives, but more speciﬁc for rejecting
true negatives. The convention in establishing diagnostic tests for
medical conditions has been to select an intermediate choice that
minimizes the total error from both false positives and false
negatives.
In the case of Alzheimer’s Disease (AD), the Consensus Report of
the Working Group on Molecular and Biochemical Markers of
Alzheimer’s Disease,
3 for example, recommended that in order to
qualify as a biomarker the measurement in question should detect
a fundamental feature of neuropathology and be validated in
neuropathologically conﬁrmed cases, and should have a
sensitivity of 480% for detecting AD and a speciﬁcity of 480%
for distinguishing other dementias.
3 The validation of diagnostic
biomarkers for AD has been facilitated by the capability for
conﬁrming the diagnosis post mortem. Thus, the current clinical
criteria for returning a diagnosis of ‘probable AD’ provide a
sensitivity of about 85% when compared with autopsy-conﬁrmed
cases. In order for a diagnostic biomarker to be clinically useful,
therefore, its sensitivity must exceed this value when correlated
with neuropathology (otherwise there is no beneﬁt to performing
the test). For example, the validation of a diagnostic neuroimaging
marker for b-amyloid pathology in AD, [F-18] ﬂorbetapir, is being
evaluated partly on the basis of correlating ﬂorbetapir-PET data
acquired antemortem with evidence of b-amyloid in the same
subjects post mortem. The results rated as positive or negative for
b-amyloid agreed in 96% of 29 individuals assessed in the
primary analysis cohort. In a secondary analysis, non-autopsy
cohort, ﬂorbetapir-PET images were rated as amyloid negative in
100% of 74 younger individuals who were cognitively normal,
4
suggesting that negative results on this test hold high negative
predictive value.
Nevertheless, the outcome of the FDA evaluation of [F-18]
ﬂorbetapir-PET for commercial use as a clinical diagnostic tool
illustrates another central principle in the validation of an imaging
diagnostic biomarker, namely that the reliability of ratings across
radiologists must be relatively high. In January 2011, the
Peripheral and Central Nervous System Drugs Advisory Committee
of the FDA recommended against approval of the new drug
application for [F-18]ﬂorbetapir injection, based largely on
concerns about the variability of ratings across readers. The
Advisory Committee chair said during an interview after the
meeting, ‘We would like to see some structured training and
evidence of consistency among readers’ (http://www.medscape.-
com/viewarticle/739297). In the pivotal trial described in the
previous paragraph, Clark et al.
4 used the median of three readers’
visual ratings on a ﬁve-point scale to assign the extent to which
the PET scan was positive for amyloid protein binding. Since
inspection of the data from individual readers ultimately raised
questions about inter-rater reliability, the FDA response focused
primarily on the need to establish a reader-training program for
market implementation that would serve to ensure reader
accuracy and consistency of interpretation of existing
[F-18]ﬂorbetapir scans. The FDA subsequently approved Amyvid
(Florbetapir F-18 Injection) for use in patients being evaluated for
AD and other causes of cognitive decline in April of 2012. A key
aspect of securing approval is that the company who will market
and distribute this PET radiopharmaceutical instituted a training
program for radiologists who will read the scans to ensure inter-
rater reliability.
The need to ensure that readers consistently can detect clear
positive or negative results extends to the clinical application of
any imaging procedure for which the results depend on the
subjective interpretation of a reader. For biological assays
that can be objectively quantiﬁed, the accuracy often is
characterized by comparing the assay results obtained for a
known standard (for example, a test sample with known
concentration for the target compound) and the reliability or
reproducibility is statistically expressed with respect to the
variability in the quantitative results obtained after performing
repeated testing on the same sample. In contrast, many types
of clinical imaging assessments depend upon subjective
interpretation, such as a radiologist’s reading of a radiographic
or nuclear medicine (for example, PET and single-photon emission
computed tomography) image on the basis of gross visual
inspection of the image. In this case, the variability of such
interpretations is evaluated by characterizing the reliability and
variability of the results obtained within and across raters.
Thus, intra-rater reliability can be established by assessing
the extent to which readings performed under blind conditions by
the same reader on the same image on different days
are in agreement, and/or the extent to which the same radiologist
renders the same results when comparing images obtained
from the same patient on different days. Similarly, inter-rater
reliability is assessed by having multiple radiologists read the
same set of images while blind to the evaluations returned
by the other readers. These intra-rater and inter-rater reliability
assessments thus evaluate, respectively, the intra-individual
variability (reﬂecting the failure of a reader to be consistent with
himself or herself) and the inter-individual variability of inter-
pretations (reﬂecting inconsistency of interpretation among
different readers).
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An important challenge in the application of neuroimaging to
psychiatric diagnosis is that the clinical utility of such tests
depends partly upon their ability to distinguish multiple condi-
tions from one other. In general, both the intra-individual and
inter-individual variability of interpretation increase in proportion
to the number of diagnostic categories that are considered
clinically relevant. In other words, the fewer the categories into
which readers are assigning results, the greater the degree of
agreement between readers. This tendency was illustrated
historically by the results of a landmark study that evaluated the
variability in interpreting chest X-ray ﬁlms during lung cancer
screening.
5 The study radiologists showed 65.1% agreement when
they were required to place the ﬁlm results into one of ﬁve
categories (suspected neoplasm, other signiﬁcant pulmonary
abnormality, cardiovascular abnormality, non-signiﬁcant
abnormality and negative), compared with 89.4% agreement if
they were instead required to place the results into only two
categories (positive or negative for signiﬁcant pulmonary
abnormality). Presumably, a diagnostic biomarker assessment
aimed at informing the differential diagnosis of psychiatric
disorders would need to address more than two categories,
however, increasing the variability of image interpretations across
readers.
In psychiatry, the need to differentiate various conditions from
each other depends partly on the clinical imperative to return
distinct treatment recommendations for different disorders.
It might be argued, for example, that for a neuroimaging
procedure to add clinical value in the evaluation of an adult
patient with impaired attention, the differential diagnosis relevant
to the treating physician includes major depressive disorder
(MDD), bipolar disorder (BD), attention deﬁcit disorder and anxiety
disorders, at a minimum,
6 since the standard of care differs
between these categories. Thus, the variability across raters will be
relatively higher (that is, lower inter-rater reliability) for a
diagnostic imaging study that must differentiate among several
psychiatric disorders that share symptomatology but require
distinct treatment approaches as compared with the case such as
that described above for [F-18]ﬂorbetapir-PET, which hinges only
on two categories (b-amyloid positive versus negative).
Furthermore, the determinations of positive and negative
predictive value are limited by the absence of an established
objective standard for establishing diagnosis in psychiatric disease
(for example, analogous to the neuropathologically veriﬁed
diagnosis of AD). Thus, the absence of certain knowledge about
the pathophysiology of psychiatric disorders will hinder the
development and validation of diagnostic biomarkers. Greater
optimism has been associated with establishing predictive
biomarkers of treatment response, pharmacodynamic biomarkers
of the effect of pharmacological probes, and surrogate biomarkers
of treatment outcome based on translational studies that
ultimately can facilitate the discovery of pathophysiology.
Nevertheless, it might be argued that the Consensus Report of
the Working Group on Molecular and Biochemical Markers of
Alzheimer’s Disease
3 reviewed above offers a template for
developing diagnostic biomarkers of psychiatric disease. Of
course, the fundamental recommendation that ‘in order to
qualify as a biomarker the measurement in question should
detect a fundamental feature of neuropathology and be validated
in neuropathologically conﬁrmed cases’ cannot be applied directly
to psychiatric disorders. Thus, the psychiatric imaging ﬁeld is
moving forward by establishing gold-standard diagnoses using
criteria-based conventions.
6 If this approach for establishing the
‘actual’ diagnosis is accepted, then the remainder of this
Consensus Report can be meaningfully adapted to biomarker
validation in psychiatric disorders. This approach would argue that
a diagnostic biomarker should have a sensitivity of 480% for
detecting a particular psychiatric disorder and a speciﬁcity of
480% for distinguishing this disorder from other psychiatric or
medical disorders. The biomarker ideally also should be reliable,
reproducible, non-invasive, simple to perform and inexpensive.
Finally, the validating data used to establish a biomarker require
conﬁrmation by at least two independent sets of qualiﬁed
investigators with the results published in peer-reviewed journals.
According to this standard, the psychiatric imaging literature
currently does not support the application of a diagnostic
neuroimaging biomarker to positively establish the presence of
any primary psychiatric disorder. Although assessments of intra-
rater and inter-rater reliabilities commonly are reported for
quantitative neuroimaging measures, these have been limited to
establishing measurement reliability (for example, of cerebral
volumes or neuroreceptor binding potential (BP)), but not to the
reliability of diagnostic interpretation. Thus, the peer-reviewed
scientiﬁc literature does not yet contain an example of a
diagnostic imaging biomarker with regard to a psychiatric
disorder or treatment for which relatively high intra- and inter-
rater reliabilities have been reported in two independent studies
or laboratories. Similarly, there is not yet a case in the literature
where neuroimaging measures obtained from the same region(s)-
of-interest has shown both a sensitivity of 480% for detecting a
particular psychiatric disorder and a speciﬁcity of 480% for
distinguishing this disorder from healthy controls or other relevant
psychiatric disorders. Nevertheless, the ensuing sections review
progress toward developing such biomarkers using state-
of-the-art neuroimaging technologies. Notably, this literature
contains several examples of individual studies for which
sensitivity and speciﬁcity approach or exceed 80%, and it is
conceivable that some of these ﬁndings ultimately may be
replicated in independent studies.
SECTION II: PROGRESS TOWARD A DIAGNOSTIC IMAGING
BIOMARKER OF DEPRESSION
A synopsis of neuroimaging abnormalities associated with mood
disorders
The neuroimaging literature has recently been extensively
reviewed by us and others elsewhere (for example, ref.
7–13) and
here we highlight only the major themes that characterize this
large corpus of data.
There is an emerging consensus that depression is character-
ized by a fundamental mood-congruent processing bias; that is, a
greater sensitivity to punishment and an impaired hedonic
capacity. In the context of functional MRI (fMRI) studies, this
cognitive bias manifests itself in two principal forms. First, relative
to healthy individuals, some depressed patients display a greater
hemodynamic response in the amygdala to negatively valenced
emotional stimuli such as sad faces and/or a reduced hemody-
namic response in the amygdala to positive stimuli such as happy
faces
14–18 (Figure 1). Second, some depressed patients show a
blunted hemodynamic response in the ventral striatum and
orbitofrontal cortex to reward stimuli that may be correlated with
anhedonia, a core symptom of depression
19–25 (Figure 2).
The genetic variants that increase the risk for developing mood
disorders are incompletely penetrant. Stated differently, indivi-
duals with genetic risk factors (for example ﬁrst-degree relatives)
for affective disorders do not necessarily become ill. They may,
however, share neurobiological traits with affected patients. This
type of disease biomarker has been termed as an endopheno-
type.
26 For example, compared with controls, healthy adolescents
with a parent with MDD showed a greater hemodynamic blood
oxygen level-dependent (BOLD) response to fearful faces in the
amygdala and nucleus accumbens, and a reduced hemodynamic
response to happy faces in nucleus accumbens.
27 Similarly,
compared with controls, both adolescents with BD and
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elevated hemodynamic response in the amygdala when pre-
sented with fearful faces.
28 The neurophysiological correlates of
response to reward may also serve as an endophenotype of mood
disorders. Healthy adolescent girls with a mother with MDD
showed lower activation in the ventral striatum to the anticipation
and receipt of a monetary reward,
29 while healthy individuals with
a depressed parent displayed an attenuated BOLD response in the
orbitofrontal cortex and anterior cingulate cortex (ACC) to a
primary reward (the taste of chocolate).
30
Figure 1. (a) Statistical parametric mapping images consisting of voxel-wise values of the t-statistic in the bilateral amygdala indicate
differences in the hemodynamic response to masked sad versus masked happy faces (SN-HN) between currently depressed people with major
depressive disorder (dMDD) and healthy controls (HCs), shown on a coronal slice located 1mm posterior to the anterior commissure.
(b) Coordinates of peak voxel t-value signifying the difference in the amygdala response to SN-HN for dMDD participants versus HCs that
correspond to the stereotaxic array of Talairach and Tournoux as the distance in millimeters from the origin (anterior commissure), with
positive x-value indicating right, positive y-value indicating anterior and positive z-value indicating dorsal. Cluster size indicates contiguous
voxels (Po0.05). Contrast b-weights are shown for speciﬁed contrasts in dMDD versus HCs for loci identiﬁed in the left (c, d) and right
amygdala (e) (reproduced with permission from Victor et al.
15).
Figure 2. Coronal slices showing consummatory reward activity (monetary gains) in basal ganglia regions are displayed for both comparison
subjects and participants with major depression. Relative to the comparison group, the major depression group showed signiﬁcantly reduced
activation in response to gain feedback in the left nucleus accumbens (a) and the caudate bilaterally (b). All contrasts are thresholded at
Po0.005. Left hemisphere is displayed on the viewer’s right (reproduced with permission from Pizzagalli et al.
25).
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indicative of reductions in the gray matter (GM) volume of
both cortical regions and subcortical structures, especially the
subgenual/pregenual ACC,
31–33 the orbitofrontal cortex,
32,34 the
hippocampus
34–36 and the striatum.
32,34–36 Many of these ﬁndings
apply also to patients with BD but these data are less
straightforward to interpret because of the neurotrophic effects
of mood stabilizers such as lithium which normalize or increase
GM volume
37–41 (Figure 3).
Reduced GM volume may constitute an endophenotype for
depression. Never-ill adolescent girls with a mother with MDD had
signiﬁcantly lower hippocampal GM density compared with
controls
42 while reduced hippocampal, medial prefrontal cortex
(PFC) and ACC volume were found in the healthy relatives of
patients with MDD.
43 In another study, healthy boys with sub-
clinical depressive symptoms were found to have smaller rostral
ACC volumes than healthy boys with no depressive symptoms.
44
An objective method for selecting potential endophenotypes from
a large set of behavioral, cognitive and morphometric imaging
markers identiﬁed GM volume changes in several regions
including the hypothalamus, hippocampus and pallidum as
among the most promising neuroimaging markers for genetic
susceptibility to recurrent MDD.
45 Similarly, increased risk of BD
was previously associated with GM reductions in the right ACC
and ventral striatum.
46
The reduction in GM volume is hypothesized to result from a
loss of neuropil
47 and this deﬁcit is associated with loss of glial
cells;
48 each of these ﬁndings are hypothesized to arise
secondarily to glutamate-induced excitotoxicity.
49 This excito-
toxicity hypothesis is partially consistent with the proton magnetic
resonance spectroscopy literature, which is indicative of a
decrease in Glx (glutamine and glutamate) in the medial PFC
and dorsolateral PFC in depressed patients with both MDD and
BD.
10,50,51 The decrease in Glx in these regions putatively reﬂects a
decrease in the intracellular component of glutamate and gluta-
mine, a ﬁnding that appears consistent with postmortem
neuropathological evidence that glial cell counts and density are
reduced in depression (reviewed in Ongur et al.
48), as well as with
additional in vivo magnetic resonance spectroscopy data showing
that the ratio of glutamine to glutamate is reduced in
depression.
10 Finally, studies showing that magnetic resonance
spectroscopy measures of GABA are abnormally decreased
in MDD suggest a decrease in GABAergic signaling
51–53
(Figure 4). The putative depression-associated increase in
glutamatergic signaling potentially is consistent with fMRI and
PET studies conducted while patients are in the resting state.
These data indicate that patients with MDD and BD display
elevated glucose metabolism and/or BOLD hemodynamic signal
in the region around the genu of the corpus callosum, that is, the
perigenual ACC
7,31,54–57 (Figure 5). Interestingly, in subjects with
MDD, elevated perigenual ACC activity at rest has also been
shown to predictive of a positive response to treatment with
antidepressant medications and transcranial magnetic stimulation
(reviewed in Pizzagalli et al.
58).
Extant data indicate that patients with mood disorders show
evidence of white matter (WM) pathology as well as reductions in
GM volume. WM hyperintensities (WMH) have been observed in a
proportion of depressed patients using T2-weighted MRI. In the
case of MDD, the prevalence of WMH is elevated signiﬁcantly in
elderly populations who also show a late age-at depression onset.
7
The histopathological correlates and clinical risk factors for WMH
in late-onset depression suggest that these MRI-based ﬁndings
signify cerebrovascular disease when observed within this clinical
context, leading to the concept of vascular depression,
59,60
a condition characterized by microvascular disease and/or
multiple subcortical infarcts of an ischemic origin. In contrast,
there are a number of reports of WMH in both adult and pediatric
patients with BD
61–63 for which the etiology remains unknown.
Diffusion tensor imaging studies are suggestive of reduced
integrity of the WM ﬁbers (particularly within the cingulum and
uncinate fasciculi) connecting the PFC with subcortical structures
in adult and pediatric patients with BD
64–69 and MDD
70–72
(Figure 6). The reduced depression-associated structural integrity
of WM tracts suggested by the diffusion tensor imaging data is
paralleled by fMRI studies, which are indicative of reduced
functional connectivity between the medial PFC, the dorsolateral
PFC and the amygdala when patients are exposed to negatively
valenced stimuli.
7,18,73,74
While there does not appear to be an increase in the number of
WMH in the unaffected relatives of patients with BD,
75,76 a
reduction in the integrity of WM ﬁbers measured with diffusion
tensor imaging has been proposed to be a marker of genetic risk
for BD. Children with a ﬁrst-degree relative with BD demonstrated
lower fractional anisotropy (FA), a measure of WM ﬁber integrity in
the superior longitudinal fasciculi
77 and in the corpus callosum
and/or inferior fronto-occipital fasciculus of the right temporal
lobe
78,79 compared with healthy control children. Further, a study
of healthy adults with BD relatives found a generalized reduction
in FA throughout the brain.
80 In the case of healthy individuals
with a family history of MDD, reduced FA was reported in the
cingulum, bilaterally,
81 and the left cingulum, splenium, superior
longitudinal fasciculi, uncinate and inferior fronto-occipital
fasciculi.
82
PET technology has enabled researchers to study neuroreceptor
function in vivo by allowing for the measurement of the BP,
which may be heuristically described as the product of the density
and afﬁnity of the receptor or protein of interest. Multiple
neuroreceptor abnormalities have been reported in mood
disorders.
12 Two of the most replicated ﬁndings are a reduction
in the postsynaptic serotonin 1A (5-HT1A) receptor BP in the
mesiotemporal cortex of patients with MDD
83–87 and BD,
86,88 and
an increase in serotonin transporter BP in regions such as the ACC,
thalamus and insula in currently depressed patients with MDD
89
and BD,
90 yet not all studies agree with these ﬁndings.
91,92
Habenula Habenula
Figure 3. Coronal magnetic resonance imaging (MRI) sections
showing the habenula and the local anatomical landmarks that
enabled its segmentation. The upper and lower panels show the
identical image. The tracing of the habenula is shown in yellow in
the lower panel. The small size of the habenula (B30mm
3) poses
signiﬁcant challenges for the accurate measurement of its volume
and functional activity (adapted from Savitz et al.
41,111).
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development of biomarkers of response to treatment using
neuroimaging
Although the broad pattern of neuroimaging abnormalities
characteristic of groups of patients with mood disorders
has been fairly well established, translating these ﬁndings into
diagnostic tests for the individual patient has proven difﬁcult. In
general, the conventional path to validate a diagnostic test
is ﬁrst to generate a potential discriminant function
from a patient cohort, and then to test this discriminant
function in an independent cohort. Currently, to our knowledge,
in the case of mood disorders, no such tests have been
validated through replication in independent cohorts subject to
peer-review.
Figure 4. Scatterplots of raw data of anterior cingulate cortex gamma-aminobutyric acid (GABA) relative to unsuppressed voxel tissue water
concentrations (GABA/w) in healthy controls and adolescents with major depressive disorder (MDD) (a) and healthy controls, non-anhedonic
adolescents with MDD, and anhedonic adolescents with MDD (b). Open circles represent subjects with melancholic MDD. Note the overlap in
the statistical distributions between the mood disorder patients and the healthy controls which is common to all current imaging modalities,
and poses challenges for the development of diagnostic tests for mood disorders (reproduced with permission from Gabbay et al.
53).
Figure 5. Increased default-mode network functional connectivity in subjects with major depression. Axial images of group default-mode
functional connectivity in depressed subjects (a) and in healthy controls (b). The contrast map in (c) demonstrates clusters in the subgenual
cingulate, thalamus and precuneus where resting-state functional connectivity was greater in depressed subjects versus controls. The t-score
bars are shown at right. Note that while the color scale range begins at 1, the minimum t-values for the analyses were 3.42 for the depressed
group map (a), 3.58 for the control group map (b) and 2.41 for the depressed versus control contrast map (c). Numbers at the bottom left of
the images refer to the z-coordinates (and for the sagittal image the x-coordinates) in the standard space of the Montreal Neurological
Institute (MNI) template. The left side of the image corresponds to the left side of the brain (reproduced with permission from Greicius et al.
57).
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geneous entities and there is considerable overlap in the statistical
distributions between patients with mood disorders and healthy
controls in regional brain volumes, receptor BP, BOLD hemody-
namic response, blood ﬂow, metabolism and other neuroimaging
measures. Thus, unlike other areas of medicine where clinical tests
have a clearly deﬁned normal range, in psychiatry there is no
consensus on what constitutes an abnormal result on an MRI or
PET scan. For instance, there are no standard normative ranges for
the volumes of cerebral structures.
Second, neuroimaging techniques—especially fMRI—are highly
sensitive to normal temporal ﬂuctuations in patient physiology or
to chemical substance intake that may have nothing to do with
mood symptoms (for example, caffeine consumption and
nicotine),
93,94 medical conditions that are commonly comorbid
with mood disorders and may themselves affect imaging
data (for example, diabetes mellitus and hypertension),
95
medication, which may independently affect neurophysiology
(for example, lithium and antidepressants),
11 and scanner
resolution and sensitivity (signal-to-noise), which will limit the
type of morphometric and functional changes that can be
measured accurately. The outcomes of PET studies are addi-
tionally sensitive to the type of radiotracer/ligand administered to
the patient and to the statistical methodology used to model BP.
The results of some types of scans may also be affected by factors
such as smoking status,
96 body mass index
97 and the number of
hours of sunshine.
98
Third, the statistical power of functional imaging methods, and
the ability to discriminate WM and GM boundaries using structural
MRI, increases with imaging time, potentially leading to a tradeoff
between accuracy and time burden/cost. Moreover, PET scanning
requires the subject to be exposed to radiation, such that the
lowest potentially effective radioactive dose is injected to ensure
safety, even though higher injected doses would be needed to
optimize the signal-to-noise ratio for some radioligands.
Fourth, in the discussion above, we emphasized the fact that
several studies have shown that healthy individuals with a
family-history of mood disorders show similar neuroimaging
abnormalities to those observed in ill patients. While these
endophenotypes can be leveraged to improve our understanding
Figure 6. Fractional anisotropy (FA) maps showing (from left to right) coronal, axial and sagittal views. Colored voxels represent regions in
which FA differs signiﬁcantly in subjects with bipolar disorder (BD) versus control subjects. Red-yellow indicates greater FA in subjects with BD
versus controls; light blue, decreased FA in subjects with BD versus controls (t43.0 and Po0.05 corrected for both (scale ranging from red
and/or blue to yellow and/or light blue)). (a) Three-dimensional views highlighting in red-yellow the central cluster in the left uncinate
fasciculus in which FA was signiﬁcantly increased in subjects with BD versus controls (t¼3.0, Po0.05 corrected). (b) Three-dimensional views
highlighting in red-yellow an orbitomedial prefrontal cortex cluster in the left uncinate fasciculus in which FA was signiﬁcantly increased in
subjects with BD versus controls (t¼4.5, Po0.05 corrected). (c) Three-dimensional views highlighting in light blue a cluster in the right
uncinate fasciculus in which FA was signiﬁcantly reduced in subjects with BD versus controls (t¼3.3, Po0.05 corrected). MNI, Montreal
Neurological Institute (reproduced with permission from Versace et al.
64).
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biomarkers poses a serious obstacle for the application of
neuroimaging to clinical diagnosis. Speciﬁcally, the presence of
imaging endophenotypes potentially may decrease diagnostic
speciﬁcity by increasing the risk for false-positive diagnoses in
healthy individuals who share genetic risk factors with depressed
relatives.
Fifth, medication is a potent confound not only because it may
affect brain structure and function, but also because it may bias
classiﬁcation algorithms. The algorithms may distinguish patients
from controls based on the impact of different classes of
medication rather than diagnosis-speciﬁc neurophysiology. Con-
versely, if an algorithm is developed on an unmedicated sample,
then it may be inaccurate when applied to a medicated subject.
Sixth, the identiﬁcation of a biomarker that can predict response
to a particular type of treatment may be confounded by the
placebo effect. In other words, if B50% of the response to an
antidepressant (or other psychiatric) medication is due to the
placebo effect,
99,100 that is, a non-speciﬁc effect, then this may
impede the identiﬁcation of a biomarker speciﬁc for response to
the pharmacological agent as opposed to a more general marker
of treatment outcome. A signiﬁcant limitation of most of the
extant literature on neuroimaging correlates of treatment
response has been the consistent absence of a placebo-control
arm (see below).
Classiﬁcation of mood disorders and/or response to treatment
using neuroimaging: empirical evidence
The development of imaging-based diagnostic algorithms that are
sufﬁciently robust to be applied across cohorts and sites will be a
signiﬁcant challenge. Currently, researchers are still in the process
of developing robust diagnostic classiﬁers within just one cohort
of patients at a time. The challenge is to determine how best to
identify the key prediction signals in the mass of data produced by
neuroimaging. One approach is to use sophisticated and powerful
statistical techniques such as machine learning. Machine learning
refers to a group of statistical methods that are used to develop
algorithms to detect patterns or regularities within high-dimen-
sional data. An empirical data training set—for example, the MRI
data of DSM-IV-diagnosed patients versus healthy controls—is
used to develop an algorithm that optimally distinguishes
between these groups. Theoretically, the computer will then be
able to make intelligent decisions about new cases based on the
examples provided in the training set. That is, the program ‘learns’
from experience.
Once an algorithm has been developed, the gold standard is to
validate the algorithm on an independent cohort. However, as
discussed below, the papers published to date have made use of a
less stringent validation method—namely the ‘leave out one’
approach. That is, all subjects except one patient–control pair are
initially chosen to comprise the training set and an algorithm that
best separates the diagnostic groups from each other is applied to
the omitted pair to predict their diagnostic status or treatment
response. The process is then iteratively applied to each subject
pair to test the ability of the algorithm to distinguish between
categories. That is, each omitted subject pair comprises one
training example. The ‘leave out one’ approach is less stringent
because one would expect to ﬁnd signiﬁcant variation across
subject samples. A proportion of this variation is likely to be
noise—that is, the confounding effects of temporal ﬂuctuations,
medications and other factors discussed above, and a proportion
of this variation is likely to result from disease heterogeneity. Only
by testing an algorithm on an independent cohort, can one
demonstrate that the discriminator is robust to these confounds.
Sun et al.
101 created cortical density maps for 36 healthy
controls and 36 patients with recent onset schizophrenia
spectrum or affective psychosis. On a group level, the patients
displayed reduced GM density in regions such as the anterior
cingulate and lateral surfaces of the prefrontal and temporal
cortices compared with the control group. Machine learning
methods were then applied to the data to test whether these
ﬁndings could be applied at the individual subject level. Using a
sparse multinomial logistic regression classiﬁer, 129 surface voxels
were linearly combined for classiﬁcation allowing for 86%
accuracy in distinguishing between patients and controls.
Clusters with the highest weightings included the frontal pole,
superior and middle temporal regions of the left hemisphere, and
the superior temporal, somatomotor and subgenual ACC regions
of the right hemisphere.
Fu et al.
102 used the voxel-wise hemodynamic response to sad
faces to distinguish acutely depressed patients with MDD (n¼19)
from healthy controls (n¼19) with 82% sensitivity and 89%
speciﬁcity. Regions with the highest vector weights included the
dorsal ACC, middle and superior frontal gyri, hippocampus,
caudate, thalamus and amygdala. The same group achieved a
less robust 65% sensitivity and 70% speciﬁcity with the use of a
working memory paradigm in 20 healthy subjects and 20
unmedicated patients with major depression.
103 Interestingly,
despite the difference in task paradigm there was some overlap in
the regions that distinguished patients and controls in the sad
face task—the caudate, and the superior and middle-frontal gyri.
In another study, the hemodynamic response of the default
mode and temporal lobe networks during an auditory oddball
paradigm was applied a priori to a sample of 14 medicated
patients with BD, type I (BD I), 21 medicated patients with
schizophrenia, and 26 healthy controls.
104 The authors were able
to distinguish BD patients from patients with schizophrenia and
healthy controls with 83% sensitivity and 100% speciﬁcity. The
accuracy of the BD versus healthy control classiﬁcation was not
provided. Most recently, Hahn et al.
105 utilized three independent
fMRI paradigms in an attempt to maximize classiﬁcation accuracy:
the passive viewing of emotionally valenced faces, and two
different versions of the monetary incentive delay task
emphasizing potential winnings and potential losses, respecti-
vely. A decision tree algorithm derived from the combination of
the imaging task classiﬁers produced a diagnostic sensitivity of
80% and a speciﬁcity of 87% in a sample of 30 patients with
depression (both unipolar and bipolar) and 30 healthy controls.
The algorithm’s ability to distinguish subjects with unipolar
depression from BD was not reported.
A Gaussian Process Classiﬁers machine-based learning approach
was recently used to distinguish healthy adolescents with and
without a parent with BD from each other with 75% sensitivity and
75% speciﬁcity.
106 A discriminating pattern of BOLD activation was
found in the superior temporal sulcus and ventromedial PFC when
subjects were presented with neutral faces in the context of happy
faces. Six out of thirteen of the high-risk adolescents who were
followed clinically, subsequently met DSM-IV criteria for MDD or
an anxiety disorder. Interestingly, these six individuals had higher
Gaussian Process Classiﬁers risk scores than the seven high-risk
subjects who did not become ill.
106 Moreover, three out of the
four high-risk subjects that the Gaussian Process Classiﬁers
algorithm incorrectly classiﬁed as low-risk, remained healthy at
follow-up.
106
Several studies have recently used machine learning methods
to evaluate response to treatment with antidepressant medica-
tion. In one such study, a whole-brain voxel-based morphometry
analysis predicted treatment response to ﬂuoxetine with 89%
sensitivity and 89% speciﬁcity. The same algorithm derived from
the voxel-based morphometry analysis only differentiated MDD
patients (n¼37) from healthy controls (n¼37) with 65%
sensitivity and 70% speciﬁcity.
107 Response to treatment was
associated with increased GM density of the rostral ACC, left
posterior cingulate cortex, left middle frontal gyrus and right
occipital cortex at baseline.
107 Gong et al.
108 used structural MRI to
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depression. Patients who failed to respond to two adequate trials
of an antidepressant were distinguished from treatment
responders with 70% sensitivity and 70% speciﬁcity based on
GM and WM volumes: treatment responders had both greater and
lower baseline volumes of different regions in the frontal,
temporal, parietal and occipital cortices, as well lower baseline
volume of the putamen.
108 Costafreda et al.
109 reported that in 16
unmedicated patients who met criteria for a major depressive
episode, pretreatment response to implicitly presented sad faces
in regions such as the dorsal ACC, midcingulate gyrus, superior
frontal gyrus, and posterior cingulate cortex predicted subsequent
response to cognitive behavioral therapy with a sensitivity of 71%
and a speciﬁcity of 86%.
Other attempts at predicting response to treatment have been
less successful. The functional imaging correlates of a verbal
working memory task only predicted response to ﬂuoxetine with
52% speciﬁcity, although sensitivity was 85%.
103 Conversely, 62%
of patients who achieved clinical remission and 75% of patients
who did not remit following 8 weeks of antidepressant treatment,
were correctly identiﬁed as responders and non-responders,
respectively, with a sad face processing task.
102
In sum, current diagnostic and treatment prediction methods
have yielded sensitivities and speciﬁcities that range from 70 to
90%. That is, B3 out of 10 patients with a mood disorder would
be incorrectly diagnosed as healthy, and B1 out of 10 healthy
individuals would be incorrectly diagnosed with a mood disorder.
Nevertheless, none of the above-mentioned studies have
achieved this degree of diagnostic success in an independent
cohort, and this will be a crucial test for the ﬁeld. Ultimately, the
patient burden and/or risk of the scan, together with its ﬁnancial
cost, will have to be balanced against the potential beneﬁts of
testing such as improved outcomes and more cost efﬁcient
treatment. The extent to which diagnostic and treatment
misclassiﬁcation will be tolerated by patients, clinicians and the
health care industry will ultimately be determined by this cost-
beneﬁt ratio.
Independent of the technical challenges involved in developing
diagnostic algorithms, we raise the issue of whether the current
approach to developing neuroimaging-based tests for the
diagnosis of psychiatric disorders is philosophically ﬂawed. The
claim that the machine learning approach will lead to objective
biomarkers of psychiatric illness that will supplant the clinical
interview is circular because the algorithms are trained to
categorize patients based on clinical (that is, DSM-IV) diagnoses.
Yet the raison d’etre of the biomarker is the future supersession of
the subjective diagnosis as the gold standard. Our current
diagnostic categories may subsume multiple distinct disorders
and thus attempting to forcibly align neurobiology with DSM
diagnoses is arguably regressive.
This view has recently been championed by the National
Institute of Mental Health in the form of the Research Domain
Criteria initiative which seeks to lay the foundations for a future
psychiatric nosology based on neuroscience and genetics rather
than clinical observation.
110 The framework for this alternative
psychiatric classiﬁcation system is formed by psychological/
behavioral ‘constructs’ that are explicitly linked to the
underlying neurobiology.
110 For example, in the context of
mood disorders, two potentially relevant constructs are ‘loss’
(HPA axis dysregulation, sustained amygdala reactivity, and so on)
and ‘response to reward attainment’ (reduced activity of the
nucleus accumbens, orbitofrontal cortex, and so on). Arguably,
imaging-based diagnostic algorithms that differentiate individuals
on the basis of Research Domain Criteria constructs such as ‘loss’
and ‘response to reward attainment’ potentially would optimize
treatment strategies in currently ill patients and allow for the
identiﬁcation of individuals at risk of developing a mood disorder
in the future.
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